EvolveImmune Therapeutics
Clinical-stage immuno-oncology company developing multispecific T cell engager therapeutics that integrate CD2 costimulation to enhance T cell activation and anti-tumor activity. The organization operates a discovery platform for target identification, advances preclinical candidate programs through IND-enabling studies and CMC activities, and is advancing a lead trispecific T cell engager into clinical trials while partnering with industry and academic groups.
Industries
Nr. of Employees
medium (51-250)
EvolveImmune Therapeutics
Products
EVOLVE104 (trispecific T cell engager targeting ULBP2/5/6)
Lead trispecific T cell engager that engages CD3 and CD2 on T cells and targets ULBP2/5/6 tumor-associated antigens; advanced through IND enabling, received FDA IND clearance and entered phase 1 clinical evaluation.
EVOLVE-105 (CD20xCD3 multispecific engager with CD2 costimulation)
Multispecific engager designed for B cell malignancies combining CD20 targeting with CD3 engagement and selective CD2 costimulation to improve durability and reduce cytokine release in preclinical models.
EVOLVE106 (multifunctional T cell engager targeting B7-H4 with CD2 costimulation)
Program targeting B7-H4 in breast cancer subtypes, designed to combine tumor antigen targeting with integrated CD2 costimulation; demonstrated preclinical activity and combination potential with other therapies.
EVOLVE205 (CD20-targeted CD2 co-stimulatory T cell engager)
CD20-targeted engager engineered in a 2:1 bispecific format designed for B cell malignancies and B cell autoimmune diseases; demonstrated enhanced in vitro killing versus benchmarks and improved in vivo efficacy in preclinical models.
EVOLVE104
A dual (2:1) CD20-targeted CD3 trispecific T cell engager with CD2 costimulation engineered for the treatment of B cell malignancies and B cell autoimmune disorders.
EVOLVE205
A dual (2:1) CD20-targeted CD3 trispecific T cell engager with CD2 costimulation engineered for the treatment of B cell malignancies and B cell autoimmune disorders.
EVOLVE104 (trispecific T cell engager targeting ULBP2/5/6)
Lead trispecific T cell engager that engages CD3 and CD2 on T cells and targets ULBP2/5/6 tumor-associated antigens; advanced through IND enabling, received FDA IND clearance and entered phase 1 clinical evaluation.
EVOLVE-105 (CD20xCD3 multispecific engager with CD2 costimulation)
Multispecific engager designed for B cell malignancies combining CD20 targeting with CD3 engagement and selective CD2 costimulation to improve durability and reduce cytokine release in preclinical models.
EVOLVE106 (multifunctional T cell engager targeting B7-H4 with CD2 costimulation)
Program targeting B7-H4 in breast cancer subtypes, designed to combine tumor antigen targeting with integrated CD2 costimulation; demonstrated preclinical activity and combination potential with other therapies.
EVOLVE205 (CD20-targeted CD2 co-stimulatory T cell engager)
CD20-targeted engager engineered in a 2:1 bispecific format designed for B cell malignancies and B cell autoimmune diseases; demonstrated enhanced in vitro killing versus benchmarks and improved in vivo efficacy in preclinical models.
EVOLVE104
A dual (2:1) CD20-targeted CD3 trispecific T cell engager with CD2 costimulation engineered for the treatment of B cell malignancies and B cell autoimmune disorders.
EVOLVE205
A dual (2:1) CD20-targeted CD3 trispecific T cell engager with CD2 costimulation engineered for the treatment of B cell malignancies and B cell autoimmune disorders.
Services
Partnered programs combining platform multispecific engager technology with industry collaborators for target discovery, candidate nomination and option-to-license arrangements.
Partnered programs combining platform multispecific engager technology with industry collaborators for target discovery, candidate nomination and option-to-license arrangements.
Expertise Areas
- Multispecific T cell engager discovery
- Translational immunology and biomarker-driven precision oncology
- CRISPR-based target discovery and genetic screening
- Preclinical in vivo and ex vivo tumor model evaluation
Key Technologies
- CRISPR-Cas9 genetic screening
- Multispecific (trispecific) T cell engager design
- CD2 costimulation-enabled T cell engager platforms
- Supported lipid bilayer immune synapse assays
News & Updates
Company announced selection of a development candidate from a collaboration with AbbVie, triggering an $18 million milestone payment under the collaboration and option-to-license agreement.
Multiple oral and poster presentations highlighted preclinical and early clinical progress of the CD2 costimulatory engager platform and the EVOLVE104 program at the AACR annual meeting.
First subject dosed in a phase 1a/1b clinical trial evaluating safety, PK/PD and preliminary efficacy in advanced urothelial and squamous cell carcinomas.
U.S. FDA cleared the investigational new drug application enabling planned first-in-human studies of the lead trispecific T cell engager.
Completed a $37M financing round with participation from existing investors and a strategic investment from Bristol Myers Squibb to fund platform and pipeline advancement including CMC for lead programs.
Entered a discovery and option-to-license partnership with a global oncology company including upfront investment and potential milestone and royalty payments to develop multispecific biologics.
Company announced selection of a development candidate from a collaboration with AbbVie, triggering an $18 million milestone payment under the collaboration and option-to-license agreement.
Multiple oral and poster presentations highlighted preclinical and early clinical progress of the CD2 costimulatory engager platform and the EVOLVE104 program at the AACR annual meeting.
First subject dosed in a phase 1a/1b clinical trial evaluating safety, PK/PD and preliminary efficacy in advanced urothelial and squamous cell carcinomas.
U.S. FDA cleared the investigational new drug application enabling planned first-in-human studies of the lead trispecific T cell engager.
Completed a $37M financing round with participation from existing investors and a strategic investment from Bristol Myers Squibb to fund platform and pipeline advancement including CMC for lead programs.
Entered a discovery and option-to-license partnership with a global oncology company including upfront investment and potential milestone and royalty payments to develop multispecific biologics.